California Stem Cell, Inc. announced today the submission of a Phase III protocol to the U.S. Food and Drug Administration for a randomized, double-blind study in metastatic melanoma.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130726005151&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130726005151&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment